Literature DB >> 24267796

Comparative study of photodynamic therapy with 5%, 10% and 20% aminolevulinic acid in the treatment of generalized recalcitrant facial verruca plana: a randomized clinical trial.

Q Li1, B Jiao, F Zhou, Q Tan, Y Ma, L Luo, J Zhai, Q Luan, C Li, G Wang, T Gao.   

Abstract

BACKGROUND: Generalised recalcitrant facial verruca plana responds poorly to current therapeutic options, including cryotherapy, topical drugs and carbon dioxide (CO2 ) laser. Case reports and uncontrolled studies suggested that topical photodynamic therapy (PDT) is effective choice of treatment free from potential complications associated with invasive therapies. AIMS: To investigate the efficacy and safety of PDT with different concentrations of photosensitiser in the treatment of verruca plana. MATERIALS &
METHODS: The two sides of a subject's face were separately randomized to receive aminolevulinic acid (ALA) of 5%, 10% or 20% concentration. All patients were irradiated with 633-nm red light for 339 J/cm(2) total dose. Complete response (CR) rate was assessed on Week 4, 8, and 16 respectively.
RESULTS: The mean overall clearance rate was 74.1%, 68.8%, and 64.6% on Week 4, 8, and 12, respectively, in the 110 treated sides. The CR rate was lower in the 5%-ALA group than in the 10%-ALA group (14.3% vs. 33.3%, p < 0.05) and 20%-ALA group (14.3% vs. 26.3%, p < 0.05) after 12 weeks. The mean severity of pain measured by visual analogue scale (VAS) scoring was 3.8 (range: 2 to 10, depending on the lesion location). The overall recurrence rate was 16.7% (4/24) on Week 12. Hyperpigmentation was observed in 61% (67/110) of all treated sides. On Week 4, 8, and 16, hyperpigmentation was more developed in the 20%-ALA group than in the other two groups (p < 0.05). DISCUSSION: In terms of complete clearance rate, the 5% ALA-PDT group was significantly inferior to the 10% and 20% ALA-PDT groups at each follow-up. In contrast, the 20% ALA group showed a higher incidence rate of transient hyperpigmentation than the other two groups.
CONCLUSIONS: This randomised clinical trial suggests that PDT with ALA of 10% concentration offers better efficacy and safety than 5% or 20% concentration for generalised recalcitrant facial verruca plana.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24267796     DOI: 10.1111/jdv.12319

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Off-label photodynamic therapy for recalcitrant facial flat warts using topical 5-aminolevulinic acid.

Authors:  Ya-Li Yang; Junjun Sang; Ning-Xin Liao; Fang Wei; Wanqin Liao; Jiang-Han Chen
Journal:  Lasers Med Sci       Date:  2016-04-08       Impact factor: 3.161

Review 2.  Photodynamic therapy in dermatology beyond non-melanoma cancer: An update.

Authors:  Xiang Wen; Yong Li; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2017-06-21       Impact factor: 3.631

3.  The Immunogenetic Aspects of Photodynamic Therapy.

Authors:  Chaw-Ning Lee; Tak-Wah Wong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Effect of a 5-aminolevulinic acid gel and 660 nm red LED light on human oral osteoblasts: a preliminary in vitro study.

Authors:  Tania Vanessa Pierfelice; Emira D'Amico; Giovanna Iezzi; Morena Petrini; Valeria Schiavone; Manuela Santalucia; Assunta Pandolfi; Camillo D'Arcangelo; Adriano Piattelli; Natalia Di Pietro
Journal:  Lasers Med Sci       Date:  2022-10-04       Impact factor: 2.555

Review 5.  Photodynamic viral inactivation: Recent advances and potential applications.

Authors:  Jace A Willis; Vsevolod Cheburkanov; Giulia Kassab; Jennifer M Soares; Kate C Blanco; Vanderlei S Bagnato; Vladislav V Yakovlev
Journal:  Appl Phys Rev       Date:  2021-06       Impact factor: 19.162

Review 6.  Chlorin, Phthalocyanine, and Porphyrin Types Derivatives in Phototreatment of Cutaneous Manifestations: A Review.

Authors:  Sarah Raquel De Annunzio; Natalia Caroline Silva Costa; Rafaela Dalbello Mezzina; Márcia A S Graminha; Carla Raquel Fontana
Journal:  Int J Mol Sci       Date:  2019-08-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.